Description: QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.
Home Page: www.quiapeg.com
Karolinska Institutet Science Park
Solna,
171 65
Sweden
Phone:
46 7 06 93 12 53
Officers
| Name | Title |
|---|---|
| Mr. Marcus Bosson | MD, CEO & Director |
| Ms. Hjordis Berg | Chief Financial Officer |
| Dr. Supaporn Sawadjoon | Head of Operations |
| Mr. Marek Kwiatkowski Ph.D. | Director |
| Dr. Vidar Wendel-Hansen M.D., Ph.D. | Deputy Director & Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.7857 |
| Price-to-Sales TTM: | 4.949 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |